• Home
  • Press
  • FCS Cancer 360-Plus magazine: Separating Fact From Fiction in Clinical Trials

FCS Cancer 360-Plus magazine: Separating Fact From Fiction in Clinical Trials

By The CCM Team

FCS 013 Cancer360Plus Fall 2019 CoverEvery therapy, drug or approach that is in place today to treat cancer had its start in a clinical trial. Florida Cancer Specialists (FCS) teams up with Sarah Cannon Research Institute, the research arm of HCA’s global cancer institute and one of the world's leading clinical research organizations, to bring innovative treatment options to patients throughout Florida. 

With a shared focus on clinical excellence and cutting-edge research, Sarah Cannon and FCS have enrolled more than 6,000 patients on innovative studies to find more effective treatments for many types of cancer.  

Researchers say the process of bringing more effective drugs to the marketplace could advance even more quickly if more people took part in the investigational studies. But they acknowledge several obstacles, including the general public’s lack of awareness and misinformation about this key aspect of the drug-approval process.

For this Cancer 360-Plus magazine feature, writer Mark Zaloudek sat down with Dr. James Reeves, FCS director of research operations, and Katie Goodman, FCS director of clinical research, for a frank discussion that resulted in a brief true/false quiz that will dispel some common misunderstandings of clinical trial research.

Read the full story

See also: Understanding & Paticipating in Clinical Trials

Consonant Custom Media
Real Stories. Real Engagement.

NYC

Mike Eisgrau
Dir. of Business Development

This email address is being protected from spambots. You need JavaScript enabled to view it.

Tampa Bay

(World Headquarters)
941-309-5380
Stephen A. Smith
Publisher | Creative Director 

Contact Us

CA

John Wark
Consulting Editor | Dir. of Business Development

This email address is being protected from spambots. You need JavaScript enabled to view it.